MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Area of Science:

• Psychiatry and Behavioral Sciences
• Pharmacology and Therapeutics
• Clinical Psychology

Background:

• Post-traumatic stress disorder (PTSD) is a debilitating condition with limited effective treatment options.
• Existing therapies for PTSD often have modest efficacy and can be poorly tolerated.
• There is a critical need for novel therapeutic interventions to address the significant unmet needs in PTSD treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) compared to placebo with identical therapy in adults with moderate to severe PTSD.
• To assess the impact of MDMA-AT on PTSD symptom severity and functional impairment.

Main Methods:

• A multi-site, randomized, double-blind, placebo-controlled phase 3 trial was conducted.
• Participants with moderate to severe PTSD received either MDMA-assisted therapy or placebo with therapy.
• Outcomes were measured using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the Sheehan Disability Scale (SDS).

Main Results:

• MDMA-AT demonstrated a statistically significant reduction in CAPS-5 total severity scores compared to placebo (P < 0.001).
• Participants receiving MDMA-AT also showed significant improvements in functional impairment as measured by the SDS (P = 0.03).
• The treatment was generally well-tolerated, with no reported deaths or serious adverse events.

Conclusions:

• MDMA-assisted therapy is an effective treatment for reducing PTSD symptoms and functional impairment in a diverse population.
• The findings support MDMA-AT as a safe and effective therapeutic option for individuals with moderate to severe PTSD.
• This study provides robust evidence for the potential of MDMA-AT in psychiatric care.